R&D Systems Inc. Tocris Bioscience Boston Biochem

PF 5081090

Cat. No. 4362

PF 5081090 C18H21FN2O6S [1312473-63-4]

Price and Availability

For PF 5081090 pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: (αR)-4-(2-Fluoro-4-methoxyphenyl)-N-­hydroxy-α-methyl-α-(methylsulfonyl)-2-oxo-1(2H)-pyri­dinebutanamide

Biological Activity

Potent antibacterial agent which disrupts lipid bilayer synthesis through inhibition of LpxC (IC50 = 1.1 nM in Pseudomonas aeruginosa); effective against a range of gram negative bacteria.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Technical Data

M.Wt:
412.43
Formula:
C18H21FN2O6S
Solubility:
Soluble to 100 mM in DMSO
Purity:
>98 %
Storage:
Store at -20°C
CAS No:
1312473-63-4

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Safety Data Sheet: View Safety Data Sheet

References

Montgomery et al (2012) Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections. J.Med.Chem. 55 (4) 1662. PMID: 22257165.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

Keywords: PF 5081090, supplier, antibacterials, gram, negative, LxpC, lipid, A, bilayer, synthesis, inhibits, inhibitors, potent, pfizer, PF5081090

Quick Order

Find multiple products by catalog number

divider line

New Product E-alerts

Sign up for email updates from Tocris

Sign-up for New Product E-alerts

Enter your email address below to sign up to receive our email updates:

divider line

Twitter Updates

Follow @Tocris on Twitter

Follow us on Twitter!

Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.